Clinical and Translational Research in Cancer 

Lines of Research

01.Clinical-translational research in breast, prostate, gynecological, digestive, and germ cell cancers

02.Translational research in the identification of epigenetic/genetic markers in early stages of cancer

03.Research on the use of new diagnostic techniques (liquid biopsy, etc.) and markers

04.Research on the relationship between the microbiota and cancer

05.Research on real-world data real world data

No results

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

Ensayo en fase III, doble ciego, aleatorizado para evaluar el cambio a AZD9833 (SERD oral de nueva generación) + inhibidor de CDK4/6 (palbociclib o abemaciclib) frente a continuar con un inhibidor de la aromatasa (letrozol o anastrozol) + inhibidor de CDK4/6 en pacientes con cáncer de mama mestastásico HR+/HER2- con mutación detectable del ESR1 sin progresión de la enfermedad durante el tratamiento de 1L con inhibidor de la aromatasa + inhibidor de CDK4/6: estudio de cambio temprano guiado por ADNtc. SERENA-6

FRANCISCO JAVIER PASCUAL LOPEZ – ENSAYO CLINICO COMERCIAL – ASTRAZENECA AB

Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2-advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial

Bofill, JS; Anton, FM; Sanchez, CAR; Calvo, EG; Melia, CH; Gil, EMC; Vidal, M; Jimenez-Rodriguez, B; Merino, LD; Janez, NM; Vazquez, RV; Salas, RD; Torres, AA; Lopez, IMA; Gregori, JG; Garcia, VQ; Rubio, EV; De la Haba-Rodriguez, J; Gonzalez-Santiago, S; Fernandez, ND; Molins, AB; De Ibarguen, BCS; Mingorance, JID; Ezquerra, MB; De Casa, S; Gimeno, A; Martin, M – 2022

A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial

Climent, MA; Font, A; Duran, I; Puente, J; Mendez-Vidal, MJ; Saez, MI; Lobera, CS; Arija, JAA; Gonzalez-Del-Alba, A; Sanchez-Hernandez, A; Fita, MJJ; Esteban, E; Alonso-Gordoa, T; Gonzalez, BM; Maroto, P; Lazaro-Quintela, M; Cassinello-Espinosa, J; Perez-Valderrama, B; Garcias, C; Castellano, D – 2022

Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein of the testis carcinoma and other cancers: Results of a Phase I/II open-label, dose escalation study

Cousin, S; Blay, JY; Garcia, IB; de Bono, JS; Le Tourneau, C; Moreno, V; Trigo, J; Hann, CL; Azad, AA; Im, SA; Cassier, PA; French, CA; Italiano, A; Keedy, VL; Plummer, R; Sablin, MP; Hemming, ML; Ferron-Brady, G; Wyce, A; Khaled, A; Datta, A; Foley, SW; McCabe, MT; Wu, YH; Horner, T; Kremer, BE; Dhar, A; O’Dwyer, PJ; Shapiro, GI; Piha-Paul, SA – 2022

Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL

Martin, M; Zielinski, C; Ruiz-Borrego, M; Carrasco, E; Turner, N; Ciruelos, EM; Munoz, M; Bermejo, B; Margeli, M; Anton, A; Kahan, Z; Csoszi, T; Casas, MI; Murillo, L; Morales, S; Alba, E; Gal-Yam, E; Guerrero-Zotano, A; Calvo, L; de la Haba-Rodriguez, J; Ramos, M; Alvarez, I; Garcia-Palomo, A; Bartlett, CH; Koehler, M; Caballero, R; Corsaro, M; Huang, X; Garcia-Saenz, JA; Chacon, JI; Swift, C; Thallinger, C; Gil-Gil, M – 2021

Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study

Park, K; Haura, EB; Leighl, NB; Mitchell, P; Shu, CA; Girard, N; Viteri, S; Han, JY; Kim, SW; Lee, CK; Sabari, JK; Spira, AI; Yang, TY; Kim, DW; Lee, KH; Sanborn, RE; Trigo, J; Goto, K; Lee, JS; Yang, JCH; Govindan, R; Bauml, JM; Garrido, P; Krebs, MG; Reckamp, KL; Xie, J; Curtin, JC; Haddish-Berhane, N; Roshak, A; Millington, D; Lorenzini, P; Thayu, M; Knoblauch, RE; Cho, BC – 2021

Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial

Andre, T; Amonkar, M; Norquist, JM; Shiu, KK; Kim, TW; Jensen, BV; Jensen, LH; Punt, CJA; Smith, D; Garcia-Carbonero, R; Sevilla, I; de la Fouchardiere, C; Rivera, F; Elez, E; Diaz, LA; Yoshino, T; Van utsem, E; Yang, P; Farooqui, M; Le, DT – 2021

Usefulness of an immunohistochemical score in advanced pancreatic neuroendocrine tumors treated with CAPTEM or everolimus

Viudez, A; Crespo, G; Dorronsoro, MLG; Arozarena, I; Marin-Mendez, JJ; Custodio, A; Benavent, M; Goni, S; Garcia-Paredes, B; Hern, J; Durantez, M; Alonso, V; Riesco, D; Lopez, C; Jimenez-Fonseca, P; San Vicente, BL; Gonzalez-Borja, I; Sevilla, I; Hernandez-Garcia, I; Carmona-Bayonas, A; Capdevila, J; Perez-Sanz, J; Garcia-Carbonero, R; Perez-Ricarte, L; Llanos, M; Vera, R; Acosta, AD – 2021

No results

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

No results

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

Members

    • Researcher in Charge
      Será Investigador de este nivel los Investigadores Responsable que lideren un grupo de investigación del Instituto y sus Co-IR. Esta categoría puede incluir investigadores muy excepcionales en su disciplina.

    Emilio Alba Conejo

    Email: 
    ORCID
    SCOPUS

      • Investigador/a Sénior
        Será Investigador de este nivel los Investigadores Responsable que lideren un grupo de investigación del Instituto y sus Co-IR. Esta categoría puede incluir investigadores muy excepcionales en su disciplina.

        No results

        The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

        • Investigador/a Asistencial Colaborador/a
          Será Investigador de este nivel los Investigadores Responsable que lideren un grupo de investigación del Instituto y sus Co-IR. Esta categoría puede incluir investigadores muy excepcionales en su disciplina.

          No results

          The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

          • Investigador/a posdoctorales y/o junior
            Será Investigador de este nivel los Investigadores Responsable que lideren un grupo de investigación del Instituto y sus Co-IR. Esta categoría puede incluir investigadores muy excepcionales en su disciplina.

            No results

            The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

            • Investigadores/as predoctorales y/o formación
              Será Investigador de este nivel los Investigadores Responsable que lideren un grupo de investigación del Instituto y sus Co-IR. Esta categoría puede incluir investigadores muy excepcionales en su disciplina.

              No results

              The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

              • Technical staff
                Será Investigador de este nivel los Investigadores Responsable que lideren un grupo de investigación del Instituto y sus Co-IR. Esta categoría puede incluir investigadores muy excepcionales en su disciplina.

                No results

                The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.